ADAP Adaptimmune Therapeutics PLC

  1. Stocks
  2. Healthcare
  3. NASDAQ: ADAP

Price (delayed)

$0.8984

Market cap

$222.19M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$0.54

Enterprise value

$100.41M

Adaptimmune is a clinical-stage biopharmaceutical company focused on the development of novel cancer immunotherapy products for people with cancer. The Company's unique SPEAR (Specific Peptide Enhanced Affinity Receptor) T-cell platform ...

Highlights
The company's revenue has surged by 122% YoY but it fell by 15% QoQ
Adaptimmune Therapeutics's gross profit has surged by 122% YoY but it has decreased by 15% QoQ
Adaptimmune Therapeutics's equity has plunged by 55% from the previous quarter and by 52% YoY
The company's quick ratio fell by 37% YoY and by 6% QoQ
Sector: Healthcare
Industry: Biotechnology
Website: http://www.adaptimmune.com
Peers: CRL ENZ NVAX EXEL

Key stats

What are the main financial stats of ADAP
Market
Shares outstanding
247.32M
Market cap
$222.19M
Enterprise value
$100.41M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
5.17
Price to sales (P/S)
3
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
1.67
Earnings
Revenue
$60.28M
EBIT
-$112.54M
EBITDA
-$102.7M
Free cash flow
-$145.56M
Per share
EPS
-$0.54
Free cash flow per share
-$0.72
Book value per share
$0.17
Revenue per share
$0.3
TBVPS
$1.4
Balance sheet
Total assets
$282.62M
Total liabilities
$243.1M
Debt
$25.24M
Equity
$39.51M
Working capital
$134.76M
Liquidity
Debt to equity
0.64
Current ratio
2.85
Quick ratio
2.07
Net debt/EBITDA
1.19
Margins
EBITDA margin
-170.4%
Gross margin
100%
Net margin
-188.9%
Operating margin
-231.8%
Efficiency
Return on assets
-37.6%
Return on equity
-134.7%
Return on invested capital
-77.7%
Return on capital employed
-53.6%
Return on sales
-186.7%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

ADAP stock price

How has the Adaptimmune Therapeutics stock price performed over time
Intraday
-9.25%
1 week
-30.36%
1 month
-38.88%
1 year
-33.45%
YTD
13.29%
QTD
-43.14%

Financial performance

How have Adaptimmune Therapeutics's revenue and profit performed over time
Revenue
$60.28M
Gross profit
$60.28M
Operating income
-$139.74M
Net income
-$113.87M
Gross margin
100%
Net margin
-188.9%
The company's revenue has surged by 122% YoY but it fell by 15% QoQ
Adaptimmune Therapeutics's gross profit has surged by 122% YoY but it has decreased by 15% QoQ
The net margin has surged by 69% year-on-year but it has declined by 41% since the previous quarter
ADAP's operating margin has soared by 62% YoY but it is down by 41% QoQ

Growth

What is Adaptimmune Therapeutics's growth rate over time

Valuation

What is Adaptimmune Therapeutics stock price valuation
P/E
N/A
P/B
5.17
P/S
3
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
1.67
Adaptimmune Therapeutics's EPS has increased by 47% YoY but it has decreased by 13% from the previous quarter
ADAP's price to book (P/B) is 137% higher than its 5-year quarterly average of 2.4 and 127% higher than its last 4 quarters average of 2.5
Adaptimmune Therapeutics's equity has plunged by 55% from the previous quarter and by 52% YoY
The company's revenue has surged by 122% YoY but it fell by 15% QoQ
The P/S is 97% below the 5-year quarterly average of 117.5 but 32% above the last 4 quarters average of 2.5

Efficiency

How efficient is Adaptimmune Therapeutics business performance
Adaptimmune Therapeutics's ROS has soared by 69% YoY but it has decreased by 44% from the previous quarter
The company's return on invested capital fell by 41% QoQ and by 9% YoY
The return on equity has declined by 35% since the previous quarter
Adaptimmune Therapeutics's return on assets has decreased by 24% QoQ but it has increased by 16% YoY

Dividends

What is ADAP's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for ADAP.

Financial health

How did Adaptimmune Therapeutics financials performed over time
ADAP's total assets is 16% greater than its total liabilities
The company's quick ratio fell by 37% YoY and by 6% QoQ
ADAP's current ratio is down by 28% YoY and by 2.4% QoQ
The debt is 36% smaller than the equity
ADAP's debt to equity has surged by 129% year-on-year and by 121% since the previous quarter
Adaptimmune Therapeutics's equity has plunged by 55% from the previous quarter and by 52% YoY

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.